Telbermin

Drug Profile

Telbermin

Alternative Names: Recombinant VEGF - Genentech; Recombinant VEGF165; rhVEGF165; Vascular endothelial growth factor 165 - Genentech

Latest Information Update: 18 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic foot ulcer; Myocardial ischaemia

Most Recent Events

  • 29 Nov 2001 Discontinued - Phase-II for Myocardial ischaemia in USA (Parenteral)
  • 17 May 2000 Two studies have been added to the Ischaemic Heart Disease pharmacodynamics section ,
  • 03 Jun 1999 A study has been added to the Ischaemic Heart Disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top